ClinConnect ClinConnect Logo
Search / Trial NCT04905797

Aspects of Self-harm - Cognition, Imaging and Treatability

Launched by REGION SKANE · May 23, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, titled "Aspects of Self-harm - Cognition, Imaging and Treatability," aims to better understand why some people engage in deliberate self-harm (DSH) and how it might be treated more effectively. Researchers are looking at various factors like thinking patterns, emotional responses, and personal backgrounds to see how they relate to self-harm. They will compare different groups of participants: those currently engaging in DSH, those who have stopped, individuals with psychiatric disorders but no history of self-harm, and healthy individuals without psychiatric issues. The goal is to gather information that could help tailor treatments for those who self-harm.

To participate in this study, individuals must be between 18 and 65 years old and currently undergoing treatment for a psychiatric disorder at an adult clinic. For the group actively engaging in self-harm, they should have harmed themselves at least five times in the past three months. Participants will be interviewed by trained physicians and undergo a series of tests that assess their thinking and decision-making abilities. Some may also take part in brain imaging tests to gain deeper insights into their cognitive processes. This study is currently recruiting participants, and those who are interested and meet the eligibility criteria may contribute valuable information to improve understanding and treatment of self-harm.

Gender

ALL

Eligibility criteria

  • Inclusion criteria for persistent DSH group:
  • Adults 18-65 years.
  • Ability to leave informed consent.
  • Understands and uses the Swedish language without significant difficulties.
  • Psychiatric disorder and ongoing treatment at an adult psychiatric clinic.
  • DSH at least five times during the last three months, and DSH at least ten times during at least one year.
  • Exclusion criteria for persistent DSH group:
  • No history of DSH, and/or DSH fewer than five times during the last three months and fewer than ten times during at least one year
  • Diagnosis of Intellectual disability
  • Diagnosis of chronic psychotic disorder
  • Hearing disability, visual impairment or motor disorder that rules out the ability to complete neurocognitive tasks
  • Inclusion criteria for those who have ceased DSH group:
  • Adults 18-65 years.
  • Ability to leave informed consent.
  • Understands and uses the Swedish language without significant difficulties.
  • Psychiatric disorder and ongoing treatment at an adult psychiatric clinic.
  • No DSH during the last three months, but DSH at least ten times during at least one year.
  • Exclusion criteria for those who have ceased DSH group:
  • Any DSH during the last three months, and/or fewer than ten times during the at least one year
  • Diagnosis of Intellectual disability
  • Diagnosis of chronic psychotic disorder
  • Hearing disability, visual impairment or motor disorder that rules out the ability to complete neurocognitive tasks
  • Inclusion criteria for psychiatric disorder with no history of DSH group:
  • Adults 18-65 years.
  • Ability to leave informed consent.
  • Understands and uses the Swedish language without significant difficulties.
  • Psychiatric disorder and ongoing treatment at an adult psychiatric clinic.
  • Exclusion criteria for psychiatric disorder with no history of DSH group:
  • Any DSH during the last three months, and more than two times during lifetime
  • Diagnosis of Intellectual disability
  • Diagnosis of chronic psychotic disorder
  • Hearing disability, visual impairment or motor disorder that rules out the ability to complete neurocognitive tasks
  • Inclusion criteria for healthy control group:
  • Adults 18-65 years.
  • Ability to leave informed consent.
  • Understands and uses the Swedish language without significant difficulties.
  • Exclusion criteria for healthy control group:
  • Diagnosed with any psychiatric disorder
  • Any DSH during the last three months, and more than two times during lifetime
  • Hearing disability, visual impairment or motor disorder that rules out the ability to complete neurocognitive tasks

About Region Skane

Region Skåne is a leading healthcare authority in Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to fostering collaboration between researchers, healthcare professionals, and patients, Region Skåne aims to enhance the understanding of various health conditions and develop effective treatment strategies. With a focus on ethical standards and patient safety, the organization plays a pivotal role in shaping the future of healthcare in the region and beyond, ensuring that clinical trials are conducted with the highest level of scientific rigor and transparency.

Locations

Lund, Skåne, Sweden

Lund, , Sweden

Patients applied

0 patients applied

Trial Officials

Sofie Westling, MD PhD

Principal Investigator

Region Skåne

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials